probably because novartis likes our heart failure therapy better or knows these drugs cant compete.
cytokinetics phase 3 molecule for heart failure with reduced ejection fraction actually had less cardiac deaths in the control group. no improvement in exercise capacity at 20 weeks. and with over 4000 patients dosed only achieved 2% p. 03 difference in the primary composite time to first event endpoint..
we got 58% reduction in heart attack and stroke and 75% reduction if there was high inflammation..
probably because novartis likes our heart failure therapy better...
-
- There are more pages in this discussion • 612 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
0.030(3.06%) |
Mkt cap ! $1.153B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.04 | 99.0¢ | $5.111M | 5.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 211966 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 136540 | 9 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |